First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

ClinicalTrials.gov ID: NCT05361395

Public ClinicalTrials.gov record NCT05361395. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung (DeLLphi-303)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

Study identification

NCT ID: NCT05361395
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Amgen; Industry
Enrollment: 184 participants

Conditions and interventions

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 24, 2022 (Actual)
Primary completion: May 30, 2030 (Estimated)
Completion: May 30, 2030 (Estimated)
Last update posted: Sep 9, 2026

2022 – 2030

United States locations

U.S. sites: 9
U.S. states: 9
U.S. cities: 9

Facility	City	State	ZIP	Site status
University of Southern California, Norris Comprehensive Cancer Center	Los Angeles	California	90033	—
Christiana Care Health Services	Newark	Delaware	19713	—
Henry Ford Health System	Detroit	Michigan	48202	—
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08901	—
New York University Grossman School of Medicine and New York University Langone Hospitals	New York	New York	10016	—
The University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	—
Avera Cancer Institute	Sioux Falls	South Dakota	57105	—
Swedish Cancer Institute Medical Oncology	Seattle	Washington	98104	—
West Virginia University Health Sciences Center	Morgantown	West Virginia	26506	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05361395, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 9, 2026 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05361395 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →